Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

deutetrabenazine

Drug and asset intelligence for deutetrabenazine with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Aurobindo Pharma →

Recent signals(2)

RegulatoryAugust 3, 2026

FDA Approves Supplement for Deutetrabenazine by Aurobindo Pharma

The FDA has approved a supplemental application for deutetrabenazine submitted by Aurobindo Pharma.

RegulatoryJuly 12, 2026

FDA Approval Status Update for Deutetrabenazine by Aurobindo Pharma

Aurobindo Pharma's application for deutetrabenazine has been submitted and is under standard review.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Aurobindo Pharma — deutetrabenazine

July 12, 2026 · N/A

Indications

Movement Disorders →

Therapeutic areas

Movement Disorders →
Neurology →
Neurology · Movement Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.